What's happening
This bill requires the New York State Department of Health to seek federal guidance on Medicaid coverage for FDA-approved prescription digital therapeutics for substance and opioid use disorders.
Why it matters
Addresses the treatment gap for substance and opioid use disorders. , especially as the COVID-19 pandemic has reduced access to in-person care, by exploring federally supported digital alternatives.
Promotes access to innovative, evidence-based therapies. prescription digital therapeutics (PDTs)—that are FDA-approved, rigorously tested, and can be used remotely, potentially benefitting Medicaid enrollees who face barriers to traditional treatment.
Could set a precedent for Medicaid coverage of software-based treatments. by clarifying if federal funds can be used, which may influence broader adoption and reimbursement of digital health technologies in New York and possibly other states.
May help reduce relapse rates and improve public health outcomes. by making it easier for vulnerable populations to maintain access to proven treatments during public health emergencies and beyond.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Expand Digital Therapy Coverage
Plain English, a few words. Used as the page title.
Sponsors
2 Co-sponsors
History
- Substituted by S559
- Rules report cal.445
- Reported
- Reported referred to rules
- Referred to ways and means
- Reported referred to ways and means
- Referred to health
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Expand Digital Therapy Coverage
Signed by Governor · Sponsor Pete Harckham
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
3642
2021-2022 Regular Sessions
IN ASSEMBLY
January 28, 2021
Introduced by M. of A. L. ROSENTHAL -- read once and referred to the Committee on Health
AN ACT in relation to determining whether the state can claim federal financial participation for coverage of and payment for certain prescription digital therapeutics
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. Legislative finding and declaration. New Yorkers in recovery for substance and opioid use disorders and in treatment for mental health conditions are losing access to in-person treatment under the state's "stay at home" and social distancing orders as part of coronavirus pandemic mitigation efforts. In recent news reports, experts warn that the coronavirus pandemic may be "a national relapse trigger" for individuals in treatment for alcohol, cocaine, methamphetamine, marijuana, and heroin addiction. Prescription Digital Therapeutics (PDTs) are new, software-based disease treatments designed to directly treat disease, tested for safety and efficacy in randomized clinical trials, evaluated by the FDA, and prescribed by healthcare providers. These therapies are designed and tested much like traditional prescription drugs with one distinction: rather than swallowing a pill or taking an injection, patients are treated with software. Certain PDTs provide clinicians and patients with evidence-based remote treatment modalities to treat substance and opioid use disorders, mental health, and other diseases and conditions. However, there is no clear statutory benefit category to allow Medicaid coverage for PDTs. In light of the promise of PDTs for the treatment of patients with substance use and opioid use disorders during the coronavirus pandemic, this legislation would require that the New York state department of health seek guidance from the Centers for Medicare and Medicaid Services relative to a coverage and reimbursement pathway for PDTs, in order to accelerate access to such therapies for enrollees.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD01006-01-1
A. 3642 2
§ 2. No later than 30 days from the effective date of this section, the New York state department of health shall request guidance from the Centers for Medicare and Medicaid Services to determine whether the state can claim federal financial participation for coverage of and payment for certain prescription digital therapeutics approved by the food and drug administration to treat substance use and opioid use disorders.
§ 3. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.